What Pharmetheus does

Pharmetheus is a privately-held, Uppsala-headquartered pharmacometrics and Model-Informed Drug Development (MIDD) consultancy founded in 2012 as a spin-off from Uppsala University. The firm employs more than 100 people, including 60+ PhD-level consultants, distributed across 15-16 countries, with staffed offices in Uppsala (Sweden), Paris (France), and Utrecht (the Netherlands). Its offering is organized around four integrated quantitative methodology platforms - MIDD, PBPK & PBBM, Pharmacometrics, and Quantitative Systems Pharmacology (QSP) - that underpin service lines such as Milestone Analysis, Embedded Scientist placements, hourly Expert Advice, and specialized practices in bioequivalence/biosimilarity, accelerated regulatory submissions, C-QTc cardiac safety, and pediatric drug development. A proprietary automated reproducible reporting system links every deliverable to source data, enabling the firm to regenerate submission-ready documentation within days of database lock.

Pharmetheus generates revenue exclusively through professional services fees, structured via milestone agreements for well-defined deliverables, embedded scientist contracts (full- or part-time placements integrated into client teams), and hourly engagements for strategic, regulatory, or technical advice. Distribution is direct enterprise sales to pharmaceutical and biotech R&D clients, supported by business development and contract managers; no channel partners or intermediaries are involved. The firm has cumulatively contributed to 100+ regulatory submissions since founding (including 1-2 NDA/BLA/MAA filings per quarter), participates in the FDA's MIDD Paired Program, and has been repeatedly recognized with Sweden's Di Gasell Prize for sustained organic growth.

Recent strategic activity is dominated by leadership transition and capacity expansion: Jonas M\u00f6ller (formerly CEO of Aixial Group CRO) succeeded Peter Milligan as CEO in 2026, the headcount crossed 100 in September 2024, and the company relocated to the LUMI building in central Uppsala. The firm is also investing in AI-assisted workflows, publishing 2026 research on using Google's Gemini-2.5-flash for regulatory document collation, signaling a pragmatic but measured adoption of generative AI as an efficiency lever rather than a core product pillar.

Name

Pharmetheus

Legal name

Pharmetheus AB

Website

https://pharmetheus.com

Company type

Private

Founded year

2012

Operating status

Operating

Headcount range

101–250 employees

Short description

Pharmetheus is a privately-held pharmacometrics consultancy spun off from Uppsala University in 2012, serving pharmaceutical and biotech clients with Model-Informed Drug Development, PBPK, pharmacometrics, and QSP services across offices in Sweden, France, and the Netherlands.

Ownership category

akta.pro rank

Product category

Pharmacometrics Consulting Services

NAICS

Scientific Research and Development Services (5417), Management Consulting Services (54161), Other Management Consulting Services (541618)

SIC

Services-Management Consulting Services (8742), Services-Commercial Physical & Biological Research (8731)

akta.pro primary industry

Clinical Trial Informatics (EDC/CTMS/eCOA/eTMF) (HLAGAJAM)

Keywords

• Pharmacometrics consulting
• Model-informed drug development
• PBPK modeling services
• Clinical pharmacology consulting
• Regulatory submission support

Headquarters

HQ city

Uppsala

HQ country

Sweden

HQ region

Europe

Offices3 records

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure

Revenue model

1. Consulting Services: Pharmetheus provides consultancy services centered around quantitative approaches to support drug research, development, and life-cycle decisions. Services include strategic planning, analysis, and regulatory support. The company offers tailored contracts including milestone agreements, embedded scientist contracts, and hourly-based expert advice contracts.

Go-to-market motion2 records

Distribution channels4 records

Marketing channels7 records

Core offering

Pharmetheus provides consulting services for pharmaceutical and biotechnology companies based on quantitative approaches to drug development. Its core offering centers on Model-Informed Drug Development (MIDD), integrating four methodology platforms — pharmacometrics, PBPK/PBBM, QSP, and strategic MIDD advisory — to support trial design, analysis, regulatory submissions, and lifecycle decisions across all drug development phases. Services are delivered through tailored engagement models including milestone-based projects, embedded scientist placements, and hourly expert advice, with a proprietary automated reporting system producing submission-ready documentation for FDA, EMA, and PMDA filings.

Product overview

Pharmetheus is a pharmacometrics and model-informed drug development (MIDD) consultancy, not a traditional software product company. Their offering consists of integrated consulting service lines organized around four quantitative methodology platforms: Model-Informed Drug Development (MIDD), PBPK & PBBM (physiologically-based pharmacokinetics and biopharmaceutics modeling), Pharmacometrics, and Quantitative Systems Pharmacology (QSP). These platforms form the scientific foundation for specialized services including Contexts of Use (trial design, regulatory interactions), Solutions (Milestone Analysis, Embedded Scientist, Expert Advice, Scientific Publication), and Specific Services (Model-Informed Bioequivalence & Biosimilarity, Accelerated Submission, C-QTc Modeling, Pediatric Strategies), complemented by Training Workshops. The interconnected platforms enable clients to access complementary quantitative approaches from a single consultancy partner.

Differentiator

Problem solved

Functional benefit

Products and services

• Milestone Analysis

Quantifiable outcome

• 100+ successful regulatory submissions since 2012, including one to two NDA, BLA, or MAA filings every quarter on accelerated timelines
• +2 more outcomes

Named customers3 records

Segments4 records

Ideal customer profiles2 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability5 records

Feature5 records

Partnerships

Eight partnerships are on record, tiered core and minor.

• DNDi (Drugs for Neglected Diseases initiative)coreStrategic or Co-development PartnerCollaboration on Cryptococcal Meningoencephalitis (CM) treatment, guiding critical decisions throughout the design and development of a new, easier-to-administer, and more patient-friendly sustained-release formulation of flucytosine. DNDi is a non-profit drug development organization focused on neglected diseases.
• Uppsala UniversitycoreStrategic or Co-development PartnerPharmetheus originated as a startup spin-off from Uppsala University in 2012. Maintains ongoing collaborations with the university including shared research initiatives and supervision of PhD students. Uppsala is described as a regional and world-leading hub for academic and industry research supporting MIDD.
• Université de ParisminorStrategic or Co-development PartnerOne of several prestigious universities with which Pharmetheus has established longstanding collaborations. Scientific advisors affiliated with academic centers of excellence.
• University of Cape TownminorStrategic or Co-development PartnerOne of several prestigious universities with which Pharmetheus has established longstanding collaborations. Scientific advisors affiliated with academic centers of excellence.
• INSERM (Institut national de la santé et de la recherche médicale)coreStrategic or Co-development PartnerStrategic research partnership for Model-Based Bioequivalence through collaboration with Pharmetheus advisor France Mentré and her research group. Contributed to foundational methodology development sponsored by the U.S. FDA.
• FDA (U.S. Food and Drug Administration)coreStrategic or Co-development PartnerPharmetheus gained expertise through involvement in collaborative research sponsored by the FDA. In 2018, FDA awarded grants to standardize model-based BE approaches, with Pharmetheus advisors and colleagues central to that work. Participated in FDA's MIDD paired program.
• The Swedish Drug Delivery Center (SweDeliver)minorStrategic or Co-development PartnerAcademic-industry consortium providing financial support and scientific input for research on subcutaneous drug delivery and mechanistic absorption modeling.
• InsightRXminorStrategic or Co-development PartnerCollaboration on research publication addressing visual predictive checks for real-world data. Joint methodological development for pharmacometric model evaluation.

Scale indicators6 records

Recent moves8 records

Expansion highlights6 records

Broad incumbents

• Simulations Plus: Simulations Plus provides PBPK, QSP, and pharmacometrics software (GastroPlus, MonolixSuite, Lixoft) plus services across drug discovery and development. It is a broader incumbent with overlapping technology and services to Pharmetheus, particularly in PBPK/PBBM modeling and biosimulation software.
• IQVIA: IQVIA is the world's largest CRO with significant clinical pharmacology and pharmacometrics capabilities embedded in its broader clinical development services. It competes with Pharmetheus on large integrated deals where sponsors prefer a one-stop-shop, while Pharmetheus competes on specialty depth and methodological flexibility.
• ICON plc: ICON is a top-3 global CRO offering clinical pharmacology, PK/PD, and regulatory consulting as part of its full-service portfolio. It competes with Pharmetheus on pharma clinical pharmacology work, particularly through its PRA Health Sciences heritage and embedded scientific consulting teams.

Direct peers

• Rosa & Co: Rosa & Co is a Quantitative Systems Pharmacology (QSP) consulting firm focused on mechanistic modeling of disease and drug action for pharma R&D. It is a direct peer in the QSP platform layer that Pharmetheus also operates in, competing for similar pharma QSP consulting engagements.
• Certara: Certara is the largest pure-play pharmacometrics and model-informed drug development software and services company, offering the Phoenix WinNonlin platform, PBPK, QSP, and regulatory submission services. It is the most direct competitor to Pharmetheus across the same pharma client base and methodology stack, though at significantly larger scale.
• Nuventra Pharma Sciences: Nuventra is a clinical pharmacology and pharmacokinetics consulting firm serving pharma and biotech across all development phases. It overlaps with Pharmetheus in pharmacokinetics, clinical pharmacology strategy, and regulatory support — though with broader CRO-style clinical operations offerings.
• Metrum Research Group: Metrum Research Group is a US-based pharmacometrics and quantitative pharmacology consulting firm offering population PK/PD modeling, MIDD, and regulatory submission support. It competes head-to-head with Pharmetheus for pharma pharmacometrics engagements and was acquired by Certara, reflecting industry consolidation dynamics.
• Pumas-AI: Pumas-AI provides pharmacometrics software (Pumas) and consulting services with strong emphasis on quantitative decision support for drug development. It overlaps with Pharmetheus across population PK/PD modeling methodology and pharma consulting engagements, with a more software-centric delivery model.
• Cognigen: Cognigen (acquired by Simulations Plus) was a specialized pharmacometrics and clinical pharmacology consulting firm serving pharma R&D. It was a close peer to Pharmetheus in population PK/PD modeling and regulatory submission support, and its acquisition illustrates the consolidation trajectory of the niche.

Regional players

• Model Answers: Model Answers is an Australia-based pharmacometrics and clinical pharmacology consulting firm. It is comparable to Pharmetheus in methodology (population PK/PD, MIDD) and pharma client base, but serves a primarily APAC-focused market rather than competing directly in Pharmetheus's European and US stronghold.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat6 records

Key risks5 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/pharmetheus

Revenue estimate

Valuation estimate

Number of profiles

Profiles15 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Pharmetheus